CBD Guides

CBD for IBS: what the evidence actually says

By the Honest CBD Co team · 6th August 2026 · Updated 20th August 2026

The evidence does not show CBD as a reliable treatment for irritable bowel syndrome. What it shows is a plausible biological mechanism, some encouraging animal work, and human trials that are small and inconsistent. A systematic review published on PMC sets out the mechanism side. The best human trial so far, a randomised placebo-controlled crossover study of CBD chewing gum in IBS patients, found no statistically significant benefit on pain at group level, though individual responses varied a lot. In the UK, neither the MHRA nor the NHS recommends CBD for IBS, and no CBD product holds an MHRA licence for it. None of that means CBD is useless for everyone. It means the evidence is early and thin, and anyone trying it should go in with clear eyes. We make CBD in Bolton and sell it online, so we have an obvious interest here. This article is our attempt to lay out what the studies actually found, what the risks are, and how to run a sensible trial if you decide to.

The short answer: CBD looks interesting in preclinical gut research and some people with IBS say it helps them, particularly with pain and anxiety-linked discomfort. Human trial evidence is limited and mixed, and the one decent randomised trial was negative overall. Treat it as an experiment alongside proven treatments, not a replacement for them.

How CBD might work in your gut
What the research actually shows
Who might plausibly benefit from trying CBD?
Safety, side effects, and drug interactions
Practical dosing and which form to choose
How to choose a quality CBD product in the UK
Where the evidence is missing and what to do about it
About Honest CBD Co and how we approach this topic
Key takeaways
The gap between what CBD promises and what the trials deliver
Where to start if you decide to try CBD for gut symptoms
Useful sources and further reading

How CBD might work in your gut

The endocannabinoid system (ECS) is a network of receptors and signalling molecules found throughout the body, including densely in the gastrointestinal tract. Three receptor types matter most for IBS: CB1, CB2 and TRPV1.

CB1 receptors sit on enteric neurons and regulate intestinal motility, secretion and visceral pain signalling. Activating them tends to slow gut transit.
CB2 receptors are concentrated on immune cells in the gut wall and modulate inflammation and immune responses, which matters in conditions like Crohn’s disease where gut inflammation is central.
TRPV1 receptors are involved in visceral hypersensitivity, the exaggerated pain response to normal gut stimuli that is a hallmark of IBS.

CBD does not bind strongly to CB1 or CB2 the way THC does. It modulates those receptors indirectly and also acts on TRPV1 and GPR55. Research published on PMC notes that blocking GPR55 reduces motility in mice, and that CBD reversed the effect, so CBD can influence gut movement through pathways that sit outside the classical cannabinoid receptors.

The gut-brain axis matters just as much. Chronic stress down-regulates CB1 receptor expression, activates the HPA stress response and drives both anxiety and visceral hypersensitivity. CBD’s anxiolytic properties are better evidenced than its direct gut effects, so it may act on IBS symptoms indirectly, by calming the stress response that amplifies gut pain. If your flares track your stress levels, that indirect route could matter more than anything happening in the bowel itself.

Preclinical work also shows CBD reducing electrically induced intestinal contractions under specific conditions, with the effect varying by intestinal region and stimulation frequency. That context-dependence is worth holding on to. CBD does not simply speed the gut up or slow it down across the board. What it does depends on the baseline state of the tissue, the dose and which part of the gut you are looking at.

On full-spectrum vs isolate: the “entourage effect” idea is that trace cannabinoids, terpenes and other plant compounds in a full-spectrum extract work together to produce effects that isolated CBD cannot. For IBS this is unproven in human trials, but it is a reasonable mechanistic hypothesis and preclinical work has explored it. Full-spectrum products contain trace THC, kept within the UK limit of 1mg per container, and THC itself has CB1 activity in the gut.

What the research actually shows

The honest picture: preclinical data are promising, human trial data are limited, inconsistent and often methodologically weak. If you have read articles claiming CBD is proven for IBS, they have gone beyond what the studies say.

The PMC systematic review of CBD and intestinal motility (searches updated to December 2022) concluded that animal and organ-bath studies support a role for CBD in modulating gut motility and inflammation, but that human studies are few, small and heterogeneous in dose, delivery method and outcome measures. No conclusive benefit for motility disorders has been demonstrated in humans.

The most rigorous human study to date is a randomised, double-blinded crossover trial of CBD chewing gum in 32 female IBS patients. Participants took symptom-driven doses, so intake varied between individuals. The headline result was negative: no statistically significant difference in pain scores compared with placebo. The trial did show high variability between individuals, meaning some participants improved and others did not, but that is a hypothesis for future work rather than a positive finding. Adherence to the chewing regimen was low, which the authors flagged as a limitation, and the format may have blunted any effect that was there.

“Authors suggest N-of-1 designs and individualised monitoring as attractive options for future research and practice, given the large inter-individual symptom variability seen in IBS.” (Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of IBS Patients)

Across the broader literature, oral CBD doses in clinical studies vary widely, with no agreed therapeutic window. Some researchers propose a bell-shaped dose response, where too little and too much are both ineffective. The variability is itself a finding. It tells you a single standard dose is unlikely to suit everyone, and that careful titration is not optional.

The common weaknesses in human IBS studies are small sample sizes, short follow-up, mixed patient populations and no standardised outcome measures. That combination makes results genuinely hard to pool or draw firm conclusions from. So the fair summary is: not proven, not disproven, and nowhere near settled.

Who might plausibly benefit from trying CBD?

IBS is not one condition. It presents as IBS-D (diarrhoea-predominant), IBS-C (constipation-predominant), IBS-M (mixed) and IBS-U (unclassified), and each subtype involves different underlying mechanisms. The reasoning below is mechanistic, not proof that any subtype responds.

IBS-D: CBD’s potential to slow gut transit via CB1 modulation makes it theoretically more relevant here. If motility is driving your symptoms, there is at least a rationale.
IBS-C: Less clear, and the same mechanism cuts the other way. CBD could in theory worsen constipation by slowing motility further.
IBS with anxiety alongside it: Arguably the strongest case for a trial. CBD’s anxiolytic effects are better evidenced than its direct gut effects, and if anxiety is amplifying visceral pain, easing it may take the edge off symptoms. Our guide on CBD for anxiety covers this in more detail.
IBS with visceral hypersensitivity and pain: TRPV1 modulation is a plausible route to pain reduction, but human evidence is thin.

Practical signs you might be a reasonable candidate for a monitored trial:

You have already tried first-line measures (dietary changes, fibre adjustment, antispasmodics) without enough relief.
Your medication regimen is stable and you can talk to your GP or pharmacist before starting.
You are willing to track symptoms properly rather than going on general impression.
You do not have a condition or take a medicine that creates a clear interaction risk (see the safety section below).

Pro Tip: Keep a simple symptom and medication diary for at least two weeks before you start. That gives you a personal baseline, so you can actually tell whether anything changes.

Safety, side effects, and drug interactions

CBD’s short and medium-term safety profile is generally tolerable, but long-term effects are not well characterised. The side effects most commonly reported are diarrhoea, fatigue and appetite changes. The diarrhoea one deserves emphasis here: if you are already managing IBS-D, CBD could make that symptom worse, particularly at higher doses.

Side effect	Notes
Diarrhoea	Dose-dependent, more common at higher doses, worth watching closely in IBS-D
Fatigue or drowsiness	Usually mild, may affect daily functioning at higher doses
Appetite changes	Can go either way, individual variation is high
Nausea	Less common, often linked to the carrier oil rather than CBD itself
Dry mouth	Mild, related to ECS modulation of salivary glands

The bigger concern for many people with IBS is drug interactions via the CYP450 enzyme system. CBD inhibits several CYP450 enzymes, particularly CYP3A4 and CYP2C19, which metabolise a lot of prescription medicines. That can push blood levels of those drugs up or down enough to matter.

Medicine classes to discuss with your GP or pharmacist before using CBD:

Antidepressants and anxiolytics (SSRIs, TCAs, benzodiazepines)
Anticoagulants (warfarin in particular, because CBD can raise warfarin levels)
Antiepileptics (CBD is itself used at prescription doses for epilepsy, so interactions get complicated)
Immunosuppressants and some cardiovascular drugs

UK regulatory context: the MHRA regulates CBD as a medicine when it carries medicinal claims. As a food supplement, CBD has to comply with the UK Novel Foods framework, and the Food Standards Agency (FSA) maintains a validated products list. No CBD product currently holds an MHRA licence for IBS, and the NHS neither recommends nor prescribes CBD for it.

Stop and get advice if: your symptoms get worse after starting, you develop new or worsening diarrhoea, you notice unusual bruising or bleeding (a possible warfarin interaction), or you get significant fatigue or mood changes.

Practical dosing and which form to choose

Format affects both bioavailability and whether you stick with it, and sticking with it affects the result. The low adherence in the chewing gum trial is a useful reminder: if a format is fiddly or unpleasant, people use it patchily, and patchy use makes it impossible to judge whether CBD is doing anything.

Format	Bioavailability	Onset	Practical notes for IBS
Oil under the tongue	Moderate (around 19%)	15-30 minutes	Easy to fine-tune the dose, good starter format
Capsules	Lower (12-15%)	45-60 minutes	Same dose every time, easiest to keep up daily
Paste	Variable (similar to oil)	15-30 minutes	Concentrated, suits people already on higher doses
Gum and edibles	Lower, food-effect dependent	60-90 minutes	Least precise, and the format where trial adherence fell down. We don’t make these

On the numbers used in research: oral CBD doses in the human studies covered by the systematic review ran from 100mg to 800mg a day, and the chewing gum trial used 50mg per gum, symptom-driven, up to 300mg a day. Those are clinical doses, well above what most people buy off the shelf.

The FSA advises healthy adults to keep CBD from food supplements to about 10mg a day. That is the official position and we will state it once, but it needs context. It is a deliberately precautionary figure. The FSA’s own advice until autumn 2023 was 70mg a day, seven times higher. Clinical research routinely uses doses in the hundreds of milligrams, as the paragraph above shows. And in our experience since 2018, most regular users settle somewhere between 25mg and 100mg or more a day. Our honest view is that 10mg is out of step with how people actually use CBD. It is guidance, not a legal limit and not a maximum dose.

A practical starting protocol:

Weeks 1-2: start at 10-20mg a day, as oil under the tongue or a capsule. Note side effects and symptom changes in your diary.
Weeks 3-4: if you are tolerating it and seeing nothing, go up to 30-40mg a day and keep monitoring.
Week 5 onwards: step up in 10-20mg increments every couple of weeks until you find the level that works for you.
When to stop: worsening symptoms, new side effects, or no discernible change after 8-12 weeks at a meaningful dose.

Capsules are the easiest format to build a daily gut routine around, because the dose is fixed and you cannot drift. Our full-spectrum CBD capsules come in 40mg, 80mg and 120mg. The 40mg is a sensible place to start out, 80mg suits regular users who have settled at a higher level, and 120mg is for experienced users who already know what they need. If you would rather creep up in smaller steps than a whole capsule, start with oil and switch to capsules once you know your number.

One caveat, and we will only say it once: build up gradually rather than jumping to a high dose, and talk to your GP or pharmacist first if you take prescription medication or you are pregnant or breastfeeding.

Pro Tip: Start your trial in a settled period, when your diet, stress levels and other medicines are stable. Adding CBD at the same time as a new diet or a new prescription makes it impossible to say what caused what.

For a broader look at hemp-based digestive health product formats, the hemp digestive health product guide offers a useful retail perspective on bioavailability and format trade-offs.

How to choose a quality CBD product in the UK

The UK CBD market is big and lightly policed at the retail end. Quality varies enormously, and a product that does not contain what the label says is not just a waste of money.

What to look for when buying CBD in the UK:

Clear dosing information. The label should tell you milligrams of CBD per millilitre or per capsule, not just a percentage. If you have to work out your dose from a percentage and a bottle size, the seller is making your life harder than it needs to be.
Honest pricing per milligram. Work out the cost per mg rather than the cost per bottle. It is the only way to compare two products fairly, and it is where a lot of high-street CBD falls apart.
UK-made or a supply chain the seller can actually explain. A reputable seller can tell you where the hemp was grown and what is in the bottle. If they cannot, it is worth looking elsewhere.
Ingredient list. Carrier oils affect taste and absorption. Avoid anything with undisclosed extras.
Novel Foods compliance. Check the FSA’s validated products list to confirm the product has been through the process.

On full-spectrum vs isolate: full-spectrum keeps the other cannabinoids and terpenes from the hemp plant, including trace THC. Isolate is pure CBD and nothing else. If the entourage effect holds, full-spectrum may have more to offer for gut symptoms, but that is unproven in IBS specifically. If you need to avoid THC completely, for work testing or your own preference, isolate is the straightforward choice.

Our full-spectrum CBD oil comes in 10ml bottles at 10% (1000mg) for £25.99 and 20% (2000mg) for £37.99. The THC-free isolate oil is flavourless and starts at £14.99 for 10ml of 10%. Both are made here in the UK in small batches, as are the capsules and the whole plant paste.

Pro Tip: Before you buy, divide the price by the milligrams of CBD in the bottle. A £15 bottle with 300mg in it is dearer than a £26 bottle with 1000mg, and that arithmetic catches a lot of people out.

Where the evidence is missing and what to do about it

The gaps in CBD and IBS research are not subtle. They are structural.

Sample sizes are too small. A trial of 32 participants cannot reliably detect modest effects or work out which patients respond.
Dosing is unstandardised. With studies spanning 100mg to 800mg a day and no agreed therapeutic window, comparing them is close to impossible.
Delivery methods vary. Chewing gum, capsules and sublingual oils have different bioavailability. Pooling their results hides real differences.
Follow-up is short. IBS is chronic. A few weeks of data says nothing about long-term safety or lasting benefit.
Subtypes are rarely separated. Lumping IBS-D, IBS-C and IBS-M into one trial buries any subgroup effect.
Outcome measures are all over the place. Pain scores, stool frequency, quality of life and global symptom ratings are not interchangeable, yet they get used as though they are.

Trials that stratify by subtype, use a standard outcome measure such as the IBS Severity Scoring System, and take an N-of-1 approach would tell us far more than another small parallel-group RCT. The chewing gum authors said as much themselves.

For readers right now, the practical position is this. Treat CBD as an experiment alongside your existing treatment, not instead of it. Keep what already works. Talk to your GP, especially if you take prescription medicines. And measure what happens rather than going on how you think you feel six weeks later.

About Honest CBD Co and how we approach this topic

Honest CBD Co is a husband-and-wife business in Bolton. We have been making CBD in small batches here in the UK since 2018 and we sell online only. The range is full-spectrum oil, THC-free isolate oil, capsules, distillate oil, amber oil, whole plant paste, isolate crystals and a body salve. That is all of it.

We are rated Excellent on Trustpilot across 732 reviews, and we think that comes down to something simple: we don’t overclaim, we price fairly per milligram, and we answer questions straight. This article is written in the same spirit. We are not telling you CBD will fix your IBS. We are telling you what the trials found, including the ones that found nothing, and how to approach it sensibly if you want to try.

“We would rather tell you the evidence is thin and sell you nothing than talk you into a product that won’t help. We have been here since 2018 on that basis.” (Honest CBD Co)

The studies cited here are linked so you can read them yourself, and we have checked what we say against UK guidance from the MHRA and the NHS. The product links are to our own range and we have said so plainly. They are an optional next step if you decide to try CBD after reading the evidence, not part of the evidence.

Key takeaways

CBD for IBS has plausible mechanisms behind it and some people report it helps them. The human trial evidence is limited, inconsistent and, in the best study so far, negative at group level. Cautious, monitored use alongside proven treatment is the only defensible approach.

Point	Details
Evidence is early, not conclusive	Preclinical data support gut mechanisms. The main human RCT showed no group-level benefit, and other human trials are small and mixed.
Safety needs watching	Common side effects include diarrhoea and fatigue. CYP450 interactions mean a word with your GP or pharmacist first if you take prescription medicines.
IBS subtype matters	IBS-D and anxiety-linked IBS have the strongest mechanistic rationale. IBS-C warrants more caution, since slowing motility could work against you.
Start low, then find your level	Begin at 10-20mg a day, give it a fair trial, and step up in 10-20mg increments until it works for you.
Honest CBD Co for UK buyers	UK-made in small batches since 2018. Full-spectrum oil from £25.99, isolate oil from £14.99, capsules in 40mg, 80mg and 120mg.

For UK safety and regulatory information, go to the NHS and the MHRA directly.

The gap between what CBD promises and what the trials deliver

There is a pattern in CBD research worth naming plainly. Preclinical studies look genuinely exciting. Animal models show CBD modulating gut motility, reducing inflammation, calming visceral pain responses. Then a human trial runs and the effect largely disappears at group level. That has happened repeatedly, not only in IBS but across several conditions.

The likeliest explanation is not that CBD does nothing. It is that IBS is extraordinarily variable between people, and group-level trials average out responses that are real but individual. The person who responds strongly and the person who does not cancel each other out in the statistics. That is why the N-of-1 recommendation from the chewing gum researchers is more than academic modesty. For a condition this variable, it may be the only sensible way to test it. It is also worth saying that the same explanation is exactly what you would expect to hear from people who want CBD to work, ourselves included, so treat it as a hypothesis rather than a defence.

What frustrates us is the binary framing that dominates the public conversation: CBD either “works” for IBS or it doesn’t. The more honest version is that CBD may work for some people with IBS, in circumstances we have not pinned down, at doses nobody has standardised. The job of research is to work out who those people are. Until that is done, the reasonable position is cautious, monitored use alongside your existing treatment. Not dismissal, and not uncritical enthusiasm.

Where to start if you decide to try CBD for gut symptoms

If you have read all that and still want to try, the practical question is what to buy. For a daily gut routine we would point you at capsules first. The dose is fixed, there is nothing to measure, and consistency is exactly what a fair trial needs.

Our full-spectrum capsules come in 40mg, 80mg and 120mg per capsule, in packs of 15, 30 or 60. A 30-pack of 40mg is £35.99, which is a month of daily use. If you would rather start finer and work upwards, the full-spectrum oil is £25.99 for a 10ml bottle at 10% (1000mg) and £37.99 at 20% (2000mg), and you can take it under the tongue a few drops at a time. If you would rather avoid THC entirely, the flavourless isolate oil is £14.99 for 10ml at 10%. For anyone already on a high daily dose, the whole plant paste is the concentrated option.

A reasonable start is 10-20mg a day for the first fortnight, taken with food, keeping the symptom diary running throughout. Everything is made by us in Bolton in small batches.

To be clear: this is the promotional bit. We publish this article and the links go to our own shop. We would still say talk to your GP before starting, particularly if you take prescription medicines.

Useful sources and further reading

The studies and resources referenced above are listed here so you can read them yourself.

Cannabidiol and intestinal motility: a systematic review (PMC), the central review covering preclinical and clinical evidence on CBD and gut motility.
Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of IBS Patients (PubMed), the 50mg chewing gum randomised controlled trial (n=32) that found no group-level benefit.
Effects of Cannabidiol Chewing Gum, full PMC entry, including the authors’ N-of-1 recommendation and the discussion of variability between individuals.
Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment (PMC), covering CB1, CB2, TRPV1 and GPR55 receptor roles in IBS.
NHS, UK health service guidance on IBS treatments and CBD safety.
MHRA, the UK medicines regulator, for any updated CBD licensing guidance.
Food Standards Agency, CBD and Novel Foods, the validated products list and Novel Foods compliance information for UK consumers.

This article is general information, not medical advice. Talk to your GP or another qualified clinician before starting CBD, particularly if you have a diagnosed condition or take prescription medicines.